{"generic":"Ziv-Aflibercept","drugs":["Zaltrap","Ziv-Aflibercept"],"mono":{"0":{"id":"jxyos0","title":"Generic Names","mono":"Ziv-Aflibercept"},"1":{"id":"jxyos1","title":"Dosing and Indications","sub":[{"id":"jxyos1b4","title":"Adult Dosing","mono":"<b>Metastatic colorectal cancer, In combination with 5-fluorouracil, leucovorin, irinotecan (FOLFIRI), in patients whose disease is resistant to or has progressed following an oxaliplatin-based regimen:<\/b> 4 mg\/kg IV infusion over 1 hour every 2 weeks until disease progression or unacceptable toxicity "},{"id":"jxyos1b5","title":"Pediatric Dosing","mono":"safety and effectiveness in pediatric patients have not been established "},{"id":"jxyos1b6","title":"Dose Adjustments","mono":"<ul><li><b>elective surgery:<\/b> interrupt therapy for at least 4 weeks prior to procedure; do not resume therapy for at least 4 weeks following a major surgical procedure and until the surgical wound is completely healed<\/li><li><b>hypertension, severe or recurrent:<\/b> temporarily interrupt therapy until controlled, reinitiate and permanently reduce dose to 2 mg\/kg IV; discontinue use if hypertensive crisis or hypertensive encephalopathy occur<\/li><li><b>proteinuria, 2 g\/24 hours:<\/b> interrupt therapy until proteinuria recovers to less than 2 g\/24 hours and resume; if proteinuria recurs, interrupt therapy again until proteinuria recovers to less than 2 g\/24 hours and reinitiate at permanently reduced dose of 2 mg\/kg IV; discontinue use if nephrotic syndrome or thrombotic microangiopathy occur<\/li><li><b>geriatric:<\/b> dose adjustment not necessary<\/li><\/ul>"},{"id":"jxyos1b7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Metastatic colorectal cancer, In combination with 5-fluorouracil, leucovorin, irinotecan (FOLFIRI), in patients whose disease is resistant to or has progressed following an oxaliplatin-based regimen<br\/>"}]},"2":{"id":"jxyos2","title":"Black Box Warning","mono":"<b>Intravenous (Solution)<\/b><br\/>Severely compromised wound healing may occur; discontinuation is required. Suspend therapy for at least 4 weeks prior to elective surgery, and do not resume for at least 4 weeks following major surgery and until the surgical wound is fully healed. Severe and sometimes fatal hemorrhage, including gastrointestinal hemorrhage, has been reported; monitoring is required. Do not administer if severe hemorrhage. Gastrointestinal perforation including fatalities may occur; discontinuation is required.<br\/>"},"3":{"id":"jxyos3","title":"Contraindications\/Warnings","sub":{"1":{"id":"jxyos3b10","title":"Precautions","mono":"<ul><li>compromised wound healing, severe, may occur; discontinuation required<\/li><li>hemorrhage, severe and sometimes fatal, including gastrointestinal, intracranial, and pulmonary hemorrhage has been reported; monitoring required; discontinuation required if severe<\/li><li>hemorrhage, severe; do not administer<\/li><li>gastrointestinal perforation including fatalities may occur; monitoring required; discontinuation required<\/li><li>surgery, elective; suspend therapy for at least 4 weeks prior to, and do not resume for at least 4 weeks following major surgery and until the surgical wound is fully healed after major or minor surgery<\/li><li>arterial thromboembolic events (eg, angina, transient ischemic attack, cerebrovascular accident) have been reported; discontinuation required<\/li><li>diarrhea and dehydration, grade 3 or 4, has been reported<\/li><li>fistulas of gastrointestinal and non-gastrointestinal sites have been reported; discontinuation required<\/li><li>geriatric patients; higher incidences of adverse events (eg, diarrhea, dizziness, asthenia, weight decrease, dehydration); monitoring for diarrhea and dehydration is recommended<\/li><li>hypertension, grade 3 or 4 including hypertensive crisis, has been reported; monitoring required; dosage adjustment and suspension or discontinuation of therapy may be needed<\/li><li>nephrotic syndrome has been reported; monitoring required; discontinuation required<\/li><li>neutropenic complications, grade 3 or 4, including febrile neutropenia and neutropenic infection, has been reported; monitoring required; interruption of therapy may be needed<\/li><li>reversible posterior encephalopathy syndrome involving neurologic sequelae and death has been reported; discontinuation of therapy required if confirmed<\/li><li>proteinuria, severe, has been reported; monitoring required; dosage adjustment and suspension of therapy may be needed<\/li><li>thrombotic microangiopathy has been reported; monitoring required; discontinuation required<\/li><li>report suspected adverse reactions to the US Food and Drug Administration at 1-800-FDA-1088 or www.fda.gov\/medwatch<\/li><\/ul>"},"2":{"id":"jxyos3b11","title":"Pregnancy Category","mono":"C (FDA)<br\/>"},"3":{"id":"jxyos3b12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}}},"5":{"id":"jxyos5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Cardiovascular:<\/b>Hypertension, All grades (41%)<\/li><li><b>Endocrine metabolic:<\/b>Weight loss (32%)<\/li><li><b>Gastrointestinal:<\/b>Abdominal pain (27%), Decrease in appetite (32%), Diarrhea (69%), Stomatitis (50%)<\/li><li><b>Hematologic:<\/b>Hemorrhage, All grades (38%), Leukopenia (78%), Neutropenia, All grades (67%), Thrombocytopenia (48%)<\/li><li><b>Hepatic:<\/b>ALT\/SGPT level raised (50%), AST\/SGOT level raised (62%)<\/li><li><b>Neurologic:<\/b>Difficulty speaking (25%), Headache (22%)<\/li><li><b>Renal:<\/b>Proteinuria, All grades (62%), Serum creatinine raised (23%)<\/li><li><b>Respiratory:<\/b>Epistaxis (28%)<\/li><li><b>Other:<\/b>Fatigue (48%), Infectious disease (46%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Angina, Hypertension, Grade 3 or 4 (grade 3, 19%; grade 4, 0.2%), Pseudoaneurysm<\/li><li><b>Dermatologic:<\/b>Impaired wound healing (grade 3, 0.3%)<\/li><li><b>Gastrointestinal:<\/b>Gastrointestinal fistula (grade 3, 0.3%), Gastrointestinal hemorrhage, Gastrointestinal perforation (0.8%)<\/li><li><b>Hematologic:<\/b>Arterial thrombosis (2.6%), Febrile neutropenia, Grade 3 or 4 (4%), Hemorrhage, Grade 3 or 4 (3%), Neutropenia, Grade 3 or 4 (37%), Thrombotic microangiopathy, Venous thromboembolism (9%)<\/li><li><b>Immunologic:<\/b>Hypersensitivity reaction (0.3%), Sepsis, Grade 3 or 4 (1.5%)<\/li><li><b>Neurologic:<\/b>Cerebrovascular accident, Intracranial hemorrhage, Posterior reversible encephalopathy syndrome (0.5%), Transient ischemic attack<\/li><li><b>Renal:<\/b>Nephrotic syndrome (0.5%), Proteinuria, Grade 3 or 4 (8%)<\/li><li><b>Respiratory:<\/b>Pulmonary embolism (5%), Pulmonary hemorrhage<\/li><\/ul>"},"6":{"id":"jxyos6","title":"Drug Name Info","sub":{"0":{"id":"jxyos6b17","title":"US Trade Names","mono":"Zaltrap<br\/>"},"3":{"id":"jxyos6b20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"jxyos6b21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"jxyos7","title":"Mechanism Of Action","mono":"Ziv-aflibercept binds to vascular endothelial growth factors VEGF-A, VEGF-B, and human PIGF-2 to inhibit the activation that produces neovascularization and vascular permeability.<br\/>"},"8":{"id":"jxyos8","title":"Pharmacokinetics","sub":{"3":{"id":"jxyos8b26","title":"Excretion","mono":"<ul><li>Total body clearance, hepatic impairment: no change<\/li><li>Total body clearance, renal impairment: no change<\/li><\/ul>"},"4":{"id":"jxyos8b27","title":"Elimination Half Life","mono":"6 days <br\/>"}}},"9":{"id":"jxyos9","title":"Administration","mono":"<b>Intravenous<\/b><br\/><ul><li>vials are intended for single-use only; discard any unused product<\/li><li>withdraw calculated dose and dilute in NS or D5W to yield concentration of ziv-aflibercept 0.6 to 8 mg\/mL<\/li><li>use diluted solution within 4 hours if stored under refrigeration<\/li><li>administer infusion over 1 hour through a 0.2 micron polyethersulfone filter<\/li><li>do NOT give as IV bolus<\/li><li>do NOT mix or administer with other products<\/li><\/ul>"},"10":{"id":"jxyos10","title":"Monitoring","mono":"<ul><li>evidence of disease response or stabilization indicates efficacy<\/li><li>CBC with differential; baseline and prior to initiation of each cycle<\/li><li>blood pressure; every 2 weeks during therapy or more frequently as clinically indicated<\/li><li>urine protein; via urine dipstick analysis and urinary protein creatinine ratio (UPCR) for development or worsening of proteinuria during therapy; obtain a 24-hour urine collection in patients with a dipstick of 2+ or more for protein or a UPCR greater than 1<\/li><\/ul>"},"11":{"id":"jxyos11","title":"How Supplied","mono":"<b>Zaltrap<\/b><br\/>Intravenous Solution: 25 MG\/ML<br\/>"},"13":{"id":"jxyos13","title":"Clinical Teaching","mono":"<ul><li>Warn patient to immediately report signs or symptoms of arterial thromboembolic events (eg, angina pectoris, TIA, stroke).<\/li><li>Advise patient to report signs or symptoms of infection, bleeding, or hypertension.<\/li><li>Tell patient to consult with physician before having surgery or procedures (tooth extractions, biopsies) as drug may delay wound healing.<\/li><li>Recommend men and women use reliable contraception during therapy and for at least 3 months after the last dose.<\/li><li>This drug may cause decreased appetite, fatigue, headache, weight loss, dysphonia, stomatitis, and proteinuria.<\/li><li>Counsel patient to report diarrhea, vomiting, dehydration, or severe abdominal pain.<\/li><\/ul>"}}}